Quantcast
Home > Quotes > AXSM
AXSM

Axsome Therapeutics, Inc. Common Stock (AXSM) Quote & Summary Data

$25.3
*  
0.28
1.12%
Get AXSM Alerts
*Delayed - data as of Jul. 18, 2019  -  Find a broker to begin trading AXSM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AXSM After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 24.15 / $ 25.80
Today's High / Low
$ 25.48 / $ 24.13
Share Volume
528,860
50 Day Avg. Daily Volume
1,262,958
Previous Close
$ 25.02
52 Week High / Low
$ 28 / $ 1.94
Market Cap
842,624,343
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
528,860
50 Day Avg. Daily Volume:
1,262,958

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.27

Trading Range

The current last sale of $25.30 is 1,204.12% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 25.48 $ 28
 Low: $ 24.13 $ 1.94

ETFs with AXSM as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.33% Invesco DWA SmallCap Momentum ETF (DWAS) +3.33 (6.47%)
1.33% Invesco DWA Tactical Multi-Asset Income ETF (DWIN) +0.85 (3.46%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, or CNS, disorders for which there are limited treatment options. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our core CNS portfolio includes four CNS product candidates, AXS­05, AXS-07, AXS-09, and AXS-12, which are being developed for multiple indications. We are conducting a Phase 3 trial with AXS-05 in treatment resistant depression, or TRD, which we refer to as the STRIDE-1 study, a Phase 2/3 trial in agitation associated with Alzheimer's disease, or AD, which we refer to as the ADVANCE-1 study. Additionally, AXS-05 is currently in a Phase 2 trial in smoking cessation and we recently completed a Phase 2 trial in major depressive disorder, or MDD, which we refer to as the ASCEND study.  ... More ...  



Risk Grade

Where does AXSM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 24.98
Open Date:
Jul. 18, 2019
Close Price:
$ 25.30
Close Date:
Jul. 18, 2019


Consensus Recommendation

Analyst Info